Research graph
References from First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2024 · External reference
10.1016/j.annonc.2022.10.003
10.1016/j.annonc.2022.10.003 · 2023 · External reference
10.1001/jama.2021.0106
10.1001/jama.2021.0106 · 2021 · External reference
Unresolved reference
2022 · External reference
10.1056/nejmoa032691
10.1056/nejmoa032691 · 2004 · External reference
Unresolved reference
External reference
10.1038/s41416-020-01140-9
10.1038/s41416-020-01140-9 · 2021 · External reference
10.1001/jama.2023.4428
10.1001/jama.2023.4428 · 2023 · External reference
10.1200/jco.2016.34.15_suppl.3504
10.1200/jco.2016.34.15_suppl.3504 · 2016 · External reference
10.6004/jnccn.2021.0012
10.6004/jnccn.2021.0012 · 2021 · External reference
Unresolved reference
External reference
10.1186/s13045-019-0718-5
10.1186/s13045-019-0718-5 · 2019 · External reference
10.1158/1078-0432.ccr-11-0659
10.1158/1078-0432.ccr-11-0659 · 2011 · External reference
10.1038/s41573-023-00671-z
10.1038/s41573-023-00671-z · 2023 · External reference
10.1007/s40262-015-0302-2
10.1007/s40262-015-0302-2 · 2016 · External reference
10.1517/13543784.2012.689287
10.1517/13543784.2012.689287 · 2012 · External reference
10.1200/jco.2012.42.6031
10.1200/jco.2012.42.6031 · 2012 · External reference
10.1200/jco.2012.45.1930
10.1200/jco.2012.45.1930 · 2013 · External reference
10.1200/jco.2010.29.4496
10.1200/jco.2010.29.4496 · 2011 · External reference
10.1200/jco.2012.42.5355
10.1200/jco.2012.42.5355 · 2012 · External reference
10.1007/s40265-018-0939-x
10.1007/s40265-018-0939-x · 2018 · External reference
10.1186/s13045-018-0664-7
10.1186/s13045-018-0664-7 · 2018 · External reference
10.1038/s41416-021-01356-3
10.1038/s41416-021-01356-3 · 2021 · External reference
10.1001/jamaoncol.2018.3039
10.1001/jamaoncol.2018.3039 · 2018 · External reference
10.1200/jco.2019.37.15_suppl.e22518
10.1200/jco.2019.37.15_suppl.e22518 · 2019 · External reference
10.1158/1078-0432.ccr-20-2950
10.1158/1078-0432.ccr-20-2950 · 2021 · External reference
10.1158/1078-0432.ccr-22-3406
10.1158/1078-0432.ccr-22-3406 · 2023 · External reference
10.1200/jco.2025.43.16_suppl.11501
10.1200/jco.2025.43.16_suppl.11501 · 2025 · External reference
10.1038/s41591-024-03132-1
10.1038/s41591-024-03132-1 · 2024 · External reference
10.1016/s1470-2045(25)00343-2
10.1016/s1470-2045(25)00343-2 · 2025 · External reference
10.1016/s1470-2045(25)00190-1
10.1016/s1470-2045(25)00190-1 · 2025 · External reference
Unresolved reference
2024 · External reference
10.1002/onco.13857
10.1002/onco.13857 · 2021 · External reference
10.1186/s12916-022-02357-6
10.1186/s12916-022-02357-6 · 2022 · External reference
10.1200/jco.2024.42.3_suppl.131
10.1200/jco.2024.42.3_suppl.131 · 2024 · External reference
10.1001/jama.2017.7105
10.1001/jama.2017.7105 · 2017 · External reference
10.1093/annonc/mdx322
10.1093/annonc/mdx322 · 2017 · External reference
10.1016/j.eclinm.2024.103004
10.1016/j.eclinm.2024.103004 · External reference
10.1016/j.ejca.2024.114036
10.1016/j.ejca.2024.114036 · 2024 · External reference
10.1016/s1470-2045(15)00122-9
10.1016/s1470-2045(15)00122-9 · 2015 · External reference
10.1016/s1470-2045(14)70330-4
10.1016/s1470-2045(14)70330-4 · 2014 · External reference
10.1016/j.ejca.2025.115694
10.1016/j.ejca.2025.115694 · External reference
10.1016/j.ejca.2023.113374
10.1016/j.ejca.2023.113374 · 2023 · External reference
10.1016/j.esmoop.2024.103654
10.1016/j.esmoop.2024.103654 · 2024 · External reference
10.1177/15330338231152350
10.1177/15330338231152350 · 2023 · External reference
10.1016/j.critrevonc.2018.03.003
10.1016/j.critrevonc.2018.03.003 · 2018 · External reference
